[1] |
Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward[J]. Nat Rev Gastroenterol Hepatol, 2021, 18:85-86.
|
[2] |
Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management[J]. Intern Med J, 2020, 50:1038-1047.
|
[3] |
Qu X, Guan P, Xu L, et al. Riligustilide alleviates hepatic insulin resistance and gluconeogenesis in T2DM mice through multitarget actions[J]. Phytother Res, 2022, 36:462-474.
|
[4] |
Adeshirlarijaney A, Gewirtz AT. Considering gut micro-biota in treatment of type 2 diabetes mellitus[J]. Gut Microbes, 2020, 11:253-264.
|
[5] |
Ye Y, Han C, Li Y, et al. Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids[J]. Biomed Pharmacother, 2020, 131:842-846.
|
[6] |
Xiao S, Liu C, Chen M, et al. Scutellariae radix and coptidis rhizoma ameliorate glycolipid metabolism of type 2 diabetic rats by modulating gut microbiota and its metabolites[J]. Appl Microbiol Biotechnol, 2020, 104:303-317
|
[7] |
Pang B, Yu X, Zhou Q, et al. Effect of Rhizoma coptidis on treating diabetes mellitus[J]. Evid Based Complement Altern Med, 2015, 205: 839-846.
|
[8] |
王丹,戚苗,赵禾笛,等. HPLC及DESI-MSI法对不同生长年限黄连次生代谢产物的动态积累及分布规律的研究[J]. 北京中医药大学学报,2022,6:612-620.
|
[9] |
李辉龙,万禄明,杨欢. 小鼠原代肝细胞糖异生研究模型的建立[J]. 生物技术通讯, 2020, 7: 704-709.
|
[10] |
Raza S, Rajak S, Upadhyay A, et al. Current treatment paradigms and emerging therapies for NAFLD/NASH[J]. Front Biosci, 2021, 26:206-237.
|
[11] |
Ota T. Prevention of NAFLD/NASH by astaxanthin and β-Cryptoxanthin[J]. Adv Exp Med Biol, 2021, 1261:231-238.
|